Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

Acticor Biotech announces its 2021 full-year financial results and gives an update on its clinical development

Paris, France, 30 March 2022 – 18:00 CEST – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, today announced its full-year results for the period ended 31 December 2021, as approved by the Board of Directors on 29 March 2022, and gave an update on its clinical development. The full-year financial report will be included in a registration document due to be published on 27 April 2022.

Gilles Avenard, Chief Executive Officer and founder of Acticor Biotech, comments: “To carry out our clinical trials in treating cardiovascular emergencies, which remains a key public health concern, we have strengthened our financial capacity thanks in particular to our successful IPO on the Euronext Growth market in Paris in October 2021. As a result of this fundraising round supported by our existing shareholders as well as a number of new shareholders, we will continue with the clinical development of our first-in-class drug glenzocimab in stroke treatment. We recently obtained very promising results for our ACTIMIS phase 1b/2a clinical trial in this indication, and which confirm the clinical interest of GPVI inhibition. In keeping with the roadmap set out at the time of our IPO, we have made a calm and enthusiastic start to 2022, with major clinical milestones to come such as recruiting the first patients in the United States for the ACTISAVE phase 2/3 clinical trial, as well as the start of the GREEN phase 2/3 trial, both in stroke treatment.”

Related posts


Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.

Read More »

Incepto, the French Digital Health Specialist, is Raising €27 million to Support Its European Development

Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.

Read More »